Director/PDMR Shareholding

AstraZeneca

15/09/2026 15:00

RNS Number : 8206U
  
AstraZeneca PLC
  
15 September 2026
  
 


15 September 2026
 
 
Transaction by Person Discharging Managerial Responsibilities
 
AstraZeneca PLC (the Company) announces that it was notified on 14 September 2026 that Michel Demaré, Non-Executive Chair of the Board, purchased 2,500 of the Company's ordinary shares of $0.25 each (Ordinary Shares) on 14 September 2026, as set out below.
 




PDMR


Position


Nature of the transaction


Date


Quantity


Price




Michel Demaré


Non-Executive Chair of the Board


Purchase of Ordinary Shares


14/09/2026


2,500


GB£121.21




 
Further details are set out in the attached notification, made in accordance with the requirements of the EU Market Abuse Regulation (as it forms part of UK law pursuant to the European Union (Withdrawal) Act 2018).
 




1
 


Details of the person discharging managerial responsibilities / person closely associated
 




a)
 


Name
 
 


Michel Demaré




2
 


Reason for the notification
 




a)
 


Position/status
 
 


Non-Executive Chair of the Board




b)
 


Initial notification /Amendment
 
 


Initial notification




3
 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 




a)
 


Name
 
 


AstraZeneca PLC




b)
 


LEI
 
 


PY6ZZQWO2IZFZC3IOL08




4
 


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
 
 




a)
 


Description of the financial instrument, type of instrument
 
Identification code
 
 


Ordinary Shares of US$0.25 each in AstraZeneca PLC
 
 
GB0009895292
 
 
 




b)
 


Nature of the transaction
 
 


Purchase of AstraZeneca PLC Ordinary Shares of US$0.25




c)
 


Price(s) and volume(s)
 
 


 




Price(s)
 


Volume(s)




£121.213296


2,500




 
 




d)
 


Aggregated information
 
 
- Aggregated volume
 
 
- Price
 
 


Not applicable - single transaction
 
 
 
 




e)
 


Date of the transaction
 
 


14 September 2026




f)
 


Place of the transaction
 
 


LON




 
 
 
AstraZeneca
AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Social Media @AstraZeneca.
 
 
Contacts
For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.
 
 
Matthew Bowden

Company Secretary
AstraZeneca PLC
 




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
DSHUVAWRNRUKARR